Healthcare resource utilization following switch or discontinuation in multiple sclerosis patients on disease modifying drugs

Journal of Medical Economics

Volumn 13, Issue 1, 2010, Pages 90-98

  Reynolds, Matthew W ^a   Stephen, Reejis ^a   Seaman, Chris ^b   Rajagopalan, Kitty ^c  

^a UNITED BIOSOURCE CORPORATION   (United States)

^b CITY UNIVERSITY OF NEW YORK   (United States)

^c BIOGEN   (United States)

Author keywords

Costs; Costs analysis; Interferon beta; Patient compliance

Indexed keywords

BETA1A INTERFERON; GLATIRAMER; INTERFERON BETA SERINE;

ADOLESCENT; ADULT; AGED; ARTICLE; BILLING AND CLAIMS; CHILD; CONTROLLED STUDY; DATA BASE; DISEASE SEVERITY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HEALTH INSURANCE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MULTIPLE SCLEROSIS;

ADOLESCENT; ADULT; AGED; ANTIRHEUMATIC AGENTS; CHILD; CHILD, PRESCHOOL; COST-BENEFIT ANALYSIS; DATABASES, FACTUAL; FEMALE; HEALTH CARE COSTS; HEALTH RESOURCES; HEALTH SERVICES; HUMANS; IMMUNOLOGIC FACTORS; INFANT; INFANT, NEWBORN; INTERFERON-BETA; LINEAR MODELS; MALE; MASSACHUSETTS; MEDICATION ADHERENCE; MIDDLE AGED; MULTIPLE SCLEROSIS; PROPORTIONAL HAZARDS MODELS; YOUNG ADULT;

EID: 77149172096     PISSN: 13696998     EISSN: None     Source Type: Journal    
DOI: 10.3111/13696990903579501     Document Type: Article

References (19)

1. Frohman EM. Multiple sclerosis. Med Clin North Am 2003;87:867-897, viii-ix.
2. Pope GC, Urato CJ, Kulas ED, et al. Prevalence, expenditures, utilization, and payment for persons with MS in insured populations. Neurology 2002;58:37-43.
3. Whetten-Goldstein K, Sloan FA, Goldstein LB, Kulas ED. A comprehensive assessment of the cost of multiple sclerosis in the United States. Mult Scler 1998;4:419-425.
4. Prescott JD, Factor S, Pill M, Levi GW. Descriptive analysis of the direct medical costs of multiple sclerosis in 2004 using administrative claims in a large nationwide database. J Manag Care Pharm 2007;13:44-52.
5. Patwardhan MB, Matchar DB, Samsa GP, et al. Cost of multiple sclerosis by level of disability: a review of literature. Mult Scler 2005;11:232-239.
6. Goodin DS, Frohman EM, Garmany GP, Jr., et al. Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology 2002;58:169-178.
7. Zannis VI, Just PW, Breslow JL. Human apolipoprotein E isoprotein subclasses are genetically determined. Am J Hum Genet 1981;33:11-24.
8. Stuart WH. Clinical management of multiple sclerosis: the treatment paradigm and issues of patient management. J Manag Care Pharm 2004;10:S19-25.
9. Rich SR, Coleman IC, Cook R, et al. Stepped-care approach to treating MS: a managed care treatment algorithm. J Manag Care Pharm 2004;10:S26-32.
10. Rio J, Nos C, Tintore M, et al. Defining the response to interfer-on-beta in relapsing-remitting multiple sclerosis patients. Ann Neurol 2006;59:344-352.
11. Coyle PK. Switching algorithms: from one immunomodulatory agent to another. J Neurol 2008;255(Suppl 1):44-50.
12. Zaffaroni M. Treatment optimisation in multiple sclerosis. Neurol Sci 2005;26(Suppl 4):S187-192.
13. Rio J, Nos C, Tintore M, et al. Assessment of different treatment failure criteria in a cohort of relapsing-remitting multiple sclerosis patients treated with interferon beta: implications for clinical trials. Ann Neurol 2002;52:400-406.
14. Clerico M, Barbero P, Contessa G, et al. Adherence to interferon-beta treatment and results of therapy switching. J Neurol Sci 2007;259:104-108.
15. Twork S, Nippert I, Scherer P, et al. Immunomodulating drugs in multiple sclerosis: compliance, satisfaction and adverse effects evaluation in a German multiple sclerosis population. Curr Med Res Opin 2007;23:1209-1215.
16. Tremlett H, Van der Mei I, Pittas F, et al. Adherence to the immunomodulatory drugs for multiple sclerosis: contrasting factors affect stopping drug and missing doses. Pharmacoepidemiol Drug Saf 2008;17:565-576.
17. Tremlett HL, Oger J. Interrupted therapy: stopping and switching of the beta-interferons prescribed for MS. Neurology 2003;61:551-554.
18. Rio J, Porcel J, Tellez N, et al. Factors related with treatment adherence to interferon beta and glatiramer acetate therapy in multiple sclerosis. Mult Scler 2005;11:306-309.
19. O'Rourke KE, Hutchinson M. Stopping beta-interferon therapy in multiple sclerosis: an analysis of stopping patterns. Mult Scler 2005;11:46-50.